Aerie plans to use the money for supporting and promoting its glaucoma drug candidate through clinical trials. The company has raised $63.5 million from investors since it was founded in 2005.
More Articles on Ophthalmology:
5 Ways Healthcare Reform Will Impact Ophthalmologists
Ophthalmic Laser Company Lumenis Receives FDA 510(k) Approval
Ophthalmologist Dr. Benjamin Hale Joins Geisinger Health System in Pennsylvania
